Site updated at Wednesday, 22 June 2016

Living with Dementia


Eli Lilly Announces FDA Approval of Amyvid For Alzheimer’s Assessment

Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced the U.S. Food and Drug Administration (FDA) approval of Amyvid™, a radioactive diagnostic agent indicated for brain imaging of beta-amyloid plaques in patients with cognitive impairment who are being evaluated for Alzheimer’s Disease and other causes… Eli Lilly Announces FDA Approval of Amyvid For Alzheimer’s Assessment   

FDA OKs Agent to Differentiate Alzheimer’s

The FDA has approved the radioactive diagnostic agent florbetapir (Amyvid) for evaluation of the causes of cognitive decline, including Alzheimer’s disease, according to Eli Lilly, developer of the compound.

Florbetapir is used in conjunction with positron emission tomography to evaluate the burden of amyloid plaques in the brain, according to Daniel Skovronsky, MD, PhD,… FDA OKs Agent to Differentiate Alzheimer’s   

Alzheimer’s Disease

alzheimer's imaging agents1 - dementias first signs1 - cerebral blood vessels1 - parkinsons diagnosis1 - artery-clogging process1 - pneumonia1 - short-term memory problems1 - dementia incident1 - tomosyn1 - memory restoration1 - voxel-based morphometry1 - brain health1 - protein alpha-synuclein1 - apolipoprotein e2 - chuanhai cao1 - wks4 - motor coordination1 - mixed forms1 - imbecility1 - memory robbing disease1 - stress management1 - parkinson’s disease2 - drug addiction1 - muscle co-ordination1 - immune system1 - multiple system atrophy1 - stress2 - brain amyloid imaging1 - dementia patients care1 - alzheimer's disease195 -